ECSP044961A - Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides - Google Patents
Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroidesInfo
- Publication number
- ECSP044961A ECSP044961A EC2004004961A ECSP044961A ECSP044961A EC SP044961 A ECSP044961 A EC SP044961A EC 2004004961 A EC2004004961 A EC 2004004961A EC SP044961 A ECSP044961 A EC SP044961A EC SP044961 A ECSP044961 A EC SP044961A
- Authority
- EC
- Ecuador
- Prior art keywords
- chlorosaliciloil
- aminocaprilico
- acid
- supply agent
- hormone fragments
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 229960001319 parathyroid hormone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan composiciones farmacéuticas para el suministro oral efectivo de una hormona paratiroides, PTH, así como métodos para la administración de las composiciones. Además, también se proporcionan métodos para estimular la formación de nuevos huesos y/o prevenir osteoporosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31304801P | 2001-08-17 | 2001-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP044961A true ECSP044961A (es) | 2004-03-23 |
Family
ID=23214149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2004004961A ECSP044961A (es) | 2001-08-17 | 2004-01-29 | Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides |
Country Status (26)
Country | Link |
---|---|
US (4) | US20040242478A1 (es) |
EP (1) | EP1420827B8 (es) |
JP (2) | JP4959917B2 (es) |
KR (1) | KR20040030120A (es) |
CN (1) | CN1279981C (es) |
AT (1) | ATE443527T1 (es) |
AU (1) | AU2002333443C1 (es) |
BR (1) | BRPI0211932B1 (es) |
CA (1) | CA2453646C (es) |
CO (1) | CO5560586A2 (es) |
CY (1) | CY1109661T1 (es) |
DE (1) | DE60233803D1 (es) |
DK (1) | DK1420827T3 (es) |
EC (1) | ECSP044961A (es) |
ES (1) | ES2333587T3 (es) |
HU (1) | HUP0401441A3 (es) |
IL (2) | IL159714A0 (es) |
MX (1) | MXPA04001418A (es) |
NO (1) | NO328069B1 (es) |
NZ (1) | NZ531018A (es) |
PL (1) | PL210258B1 (es) |
PT (1) | PT1420827E (es) |
RU (1) | RU2322256C2 (es) |
SI (1) | SI1420827T1 (es) |
WO (1) | WO2003015822A1 (es) |
ZA (1) | ZA200400242B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307145B6 (cs) * | 2001-06-01 | 2018-02-07 | Novartis Ag | Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby |
NZ531018A (en) * | 2001-08-17 | 2006-03-31 | Novartis Ag | 5-CNAC as oral delivery agent for parathyroid hormone fragments |
JP2006515829A (ja) * | 2002-04-10 | 2006-06-08 | ユニバーシティ オブ バージニア パテント ファウンデーション | 炎症性疾病の処置のための、a2aアデノシン受容体アゴニストの使用 |
US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
CN1856321B (zh) | 2003-07-23 | 2012-10-03 | 诺瓦提斯公司 | 降钙素在骨关节炎中的用途 |
GB0427600D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
WO2006076692A1 (en) * | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
WO2006135915A2 (en) * | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US8026392B2 (en) | 2005-09-19 | 2011-09-27 | Emisphere Technologies, Inc. | Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid |
GB0522566D0 (en) | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
AU2007289344B2 (en) * | 2006-08-31 | 2011-04-14 | Novartis Ag | Pharmaceutical compositions comprising hGH for oral delivery |
DE602008006700D1 (es) | 2007-03-02 | 2011-06-16 | Novartis Ag | |
JP5555634B2 (ja) | 2007-11-02 | 2014-07-23 | エミスフェア テクノロジーズ インコーポレイティッド | ビタミンb12欠乏症を治療するための方法 |
JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
IL283258B2 (en) * | 2015-02-09 | 2023-11-01 | Entera Bio Ltd | A preparation for the treatment of hypothyroidism |
KR101796604B1 (ko) * | 2016-08-30 | 2017-11-10 | 목포대학교 산학협력단 | 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
CA2124792C (en) * | 1991-12-17 | 2000-07-04 | Ann D. Geddes | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
KR100291620B1 (ko) * | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CA2319672C (en) * | 1997-02-07 | 2011-01-04 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
JP2003533167A (ja) * | 1998-11-25 | 2003-11-11 | ザ ゼネラル ホスピタル コーポレーション | アミノ末端改変副甲状腺ホルモン(pth)アナログ |
ES2235854T3 (es) * | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
CA2402719C (en) * | 2000-03-21 | 2012-03-20 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
CZ307145B6 (cs) | 2001-06-01 | 2018-02-07 | Novartis Ag | Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby |
NZ531018A (en) * | 2001-08-17 | 2006-03-31 | Novartis Ag | 5-CNAC as oral delivery agent for parathyroid hormone fragments |
DE602004023093D1 (de) * | 2003-07-11 | 2009-10-22 | Novartis Ag | N mit einem abgabemittel in mikronisierter form |
-
2002
- 2002-08-16 NZ NZ531018A patent/NZ531018A/xx not_active IP Right Cessation
- 2002-08-16 AU AU2002333443A patent/AU2002333443C1/en not_active Ceased
- 2002-08-16 EP EP02794796A patent/EP1420827B8/en not_active Expired - Lifetime
- 2002-08-16 RU RU2004107899/15A patent/RU2322256C2/ru not_active IP Right Cessation
- 2002-08-16 DE DE60233803T patent/DE60233803D1/de not_active Expired - Lifetime
- 2002-08-16 SI SI200230866T patent/SI1420827T1/sl unknown
- 2002-08-16 ES ES02794796T patent/ES2333587T3/es not_active Expired - Lifetime
- 2002-08-16 PL PL365388A patent/PL210258B1/pl unknown
- 2002-08-16 DK DK02794796T patent/DK1420827T3/da active
- 2002-08-16 US US10/484,331 patent/US20040242478A1/en not_active Abandoned
- 2002-08-16 PT PT02794796T patent/PT1420827E/pt unknown
- 2002-08-16 MX MXPA04001418A patent/MXPA04001418A/es active IP Right Grant
- 2002-08-16 AT AT02794796T patent/ATE443527T1/de active
- 2002-08-16 IL IL15971402A patent/IL159714A0/xx unknown
- 2002-08-16 WO PCT/EP2002/009181 patent/WO2003015822A1/en active Application Filing
- 2002-08-16 JP JP2003520780A patent/JP4959917B2/ja not_active Expired - Fee Related
- 2002-08-16 CN CNB028160843A patent/CN1279981C/zh not_active Expired - Fee Related
- 2002-08-16 BR BRPI0211932A patent/BRPI0211932B1/pt not_active IP Right Cessation
- 2002-08-16 KR KR10-2004-7002277A patent/KR20040030120A/ko active Search and Examination
- 2002-08-16 HU HU0401441A patent/HUP0401441A3/hu unknown
- 2002-08-16 CA CA002453646A patent/CA2453646C/en not_active Expired - Lifetime
-
2004
- 2004-01-05 IL IL159714A patent/IL159714A/en not_active IP Right Cessation
- 2004-01-13 ZA ZA200400242A patent/ZA200400242B/en unknown
- 2004-01-29 EC EC2004004961A patent/ECSP044961A/es unknown
- 2004-02-10 NO NO20040598A patent/NO328069B1/no not_active IP Right Cessation
- 2004-02-17 CO CO04013136A patent/CO5560586A2/es not_active Application Discontinuation
-
2006
- 2006-05-30 US US11/443,528 patent/US20060217313A1/en not_active Abandoned
-
2009
- 2009-06-09 JP JP2009138067A patent/JP2009242410A/ja not_active Withdrawn
- 2009-07-01 US US12/495,966 patent/US20090264367A1/en not_active Abandoned
- 2009-11-25 CY CY20091101231T patent/CY1109661T1/el unknown
-
2011
- 2011-12-15 US US13/327,114 patent/US9272040B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP044961A (es) | Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides | |
CL2009000648A1 (es) | Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02). | |
ES2190244T3 (es) | Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales. | |
SE0100568D0 (sv) | Compounds | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
MXPA05011208A (es) | Uso de ivermectina para el tratamiento de desordenes dermatologicos. | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
WO2002067967A3 (en) | Method of treating rhinitis or sinusitis | |
ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
UY27886A1 (es) | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco. | |
NO20061236L (no) | Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton | |
ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
SE0100566D0 (sv) | Compounds | |
PE20000644A1 (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea | |
AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
GT200400134A (es) | Sistemas emulsionantes que contienen derivados de azetidina | |
CL2004000767A1 (es) | Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos. | |
PE20000633A1 (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
SE0101692D0 (sv) | Compounds | |
SE0202365D0 (sv) | New formulation and use thereof | |
WO2007023281A3 (en) | Biologically active compounds | |
AR013492A1 (es) | Medicamento veterinario que contiene la coriogonadotrofina equina nativa o modificada para inducir la ovulacion en la yegua y estimular la produccion detestosterona en el semental. |